Vycor Medical Inc. announced that Richard P. Denness will be joining as new Chief Executive Officer, replacing Ken Coviello. During this transition period, Ken will retain a role with the company on a consultancy basis. Since the acquisitions of NovaVision Inc. and Sight Science Limited, Vycor has become an international group of greater complexity with several businesses. Richard Denness is a healthcare executive with global experience who has held senior management positions at UCB Inc., Schwarz Pharma US, Schering-Plough and IVAX Corporation. Ken had indicated to the Board a desire to pursue personal interests and pass the role on to a new executive to take Vycor forward to the next level, once an appropriate successor could be found.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
